179 related articles for article (PubMed ID: 3460700)
1. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
[TBL] [Abstract][Full Text] [Related]
2. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Warrell RP; Arlin ZA; Kempin SJ; Young CW
Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
[TBL] [Abstract][Full Text] [Related]
5. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
6. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
[TBL] [Abstract][Full Text] [Related]
8. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of aclarubicin in acute myeloblastic leukemia.
Case DC; Ervin TJ; Boyd MA; Bove LG; Sonneborn HL; Paul SD
Am J Clin Oncol; 1987 Dec; 10(6):523-6. PubMed ID: 3479891
[TBL] [Abstract][Full Text] [Related]
10. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
11. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of vindesine in patients with acute leukemia.
Sklaroff RB; Arlin Z; Young CW
Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307
[TBL] [Abstract][Full Text] [Related]
14. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
[TBL] [Abstract][Full Text] [Related]
15. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
Ryan DH; Kopecky KJ; Head D; Gumbart CN; Grever MR; Karanes C; Weick JK; Coltman CA
Cancer Treat Rep; 1987; 71(7-8):713-6. PubMed ID: 3475171
[TBL] [Abstract][Full Text] [Related]
17. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
18. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
Warrell RP
Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
[TBL] [Abstract][Full Text] [Related]
19. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
20. Aclarubicin-associated QTc prolongation and ventricular fibrillation.
Iwata N; Karasawa M; Omine M; Maekawa T; Suzuki T; Kawai Y
Cancer Treat Rep; 1984 Mar; 68(3):527-9. PubMed ID: 6584207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
